Colossal Biosciences Lands $60M Series A
DALLAS, TX, Colossal Biosciences, a biosciences and genetic engineering company, announced an oversubscribed $60M Series A financing.
DALLAS, TX, Colossal Biosciences, a biosciences and genetic engineering company, announced an oversubscribed $60M Series A financing led by Thomas Tull and At One Ventures with participation from Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, Arch Ventures co-founder Robert Nelsen, Paris Hilton, Bold Capital, First Light Capital Group, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity, Draper Associates, Charles Hoskinson, among others, bringing total funding to $75M.
Colossal was founded by emerging technology and software entrepreneur Ben Lamm and world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about